Sol-Gel reported a net loss of $0.4 million for the third quarter of 2024 and loss of $0.01 per basic and diluted share, compared to a net loss of $5.7 million and a loss of $0.21 per basic and ...
(NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for ...
About PYRUKYND® (mitapivat) PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, and for the ...
An Aberdeen councillor who described an opponent as a "New Scot" breached the code of conduct, it has been ruled. The SNP's Kairin van Sweeden made the remark against Labour's Deena Tissera during ...
Some mental health problems last for only short periods of time, while others, potentially, last a lifetime. Listed in the directory below you will find some additional information regarding some of ...